Zura Bio (NASDAQ: ZURA) director receives grant of 51,000 share options

Rhea-AI Filing Summary

Zura Bio Ltd director Jennifer Jarrett received a grant of share options covering 51,000 Class A Ordinary Shares. The options have an exercise price of $3.62 per share and expire on June 17, 2036. Following this grant, she holds options on 51,000 shares directly.

The option award vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion will vest immediately before the next annual shareholder meeting after the grant date, subject to her continued service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jarrett Jennifer

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	51,000	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 51,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 51,000 options Exercise price: $3.62 per share Expiration date: June 17, 2036 +2 more

5 metrics

Options granted 51,000 options Share Option (Right to Buy) granted to director

Exercise price $3.62 per share Option exercise price for Class A Ordinary Shares

Expiration date June 17, 2036 Option term end date

Underlying shares 51,000 shares Class A Ordinary Shares underlying the options

Post-transaction holdings 51,000 options Total derivative holdings following grant

Key Terms

Share Option (Right to Buy), Class A Ordinary Shares, Grant, award, or other acquisition, vests in twelve substantially equal monthly installments, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Class A Ordinary Shares financial

"underlying_security_title: "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vests in twelve substantially equal monthly installments financial

"This option vests in twelve substantially equal monthly installments over a one-year period"

expiration date financial

"expiration_date: "2036-06-17T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 04:16 PM Accepted by SEC EDGAR 06/22/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NEVADA 89014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.62	06/17/2026		A		51,000		(1)	06/17/2036	Class A Ordinary Shares	51,000	$0	51,000	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Zura Bio (ZURA) report for Jennifer Jarrett?

Jennifer Jarrett received a grant of 51,000 share options in Zura Bio Ltd. These options allow her to buy Class A Ordinary Shares at a fixed exercise price, functioning as part of her equity-based compensation package as a director.

What are the key terms of Jennifer Jarrett’s Zura Bio option grant?

The grant covers 51,000 share options with an exercise price of $3.62 per share and an expiration date of June 17, 2036. Each option relates to one Class A Ordinary Share of Zura Bio Ltd.

How do Jennifer Jarrett’s Zura Bio options vest over time?

The option grant vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion vests immediately before the next annual shareholder meeting, contingent on her continued service.

Does this Form 4 show a market purchase or sale of Zura Bio shares?

No, the Form 4 reports a grant of share options, not an open-market trade. The transaction code is “A,” indicating a grant, award, or other acquisition of derivative securities as compensation rather than a buy or sell in the market.

What is Jennifer Jarrett’s position in Zura Bio after this option grant?

After the transaction, she holds 51,000 share options directly, each tied to a Class A Ordinary Share. These options are exercisable at $3.62 per share and represent her reported derivative holdings following this specific grant.